Page 1,779«..1020..1,7781,7791,7801,781..1,7901,800..»

Beneficial use of stem cells and telomere science is to …

Posted: July 2, 2015 at 12:51 am

Stem cells hold a lot of potential to help the humans discover cures for different ailments that are responsible for the death of thousands every year.

With the passage of time, medical science is making great advances to come up with better treatment methods that have the capability of providing better results. The human body is designed to have limited age, and after the passage of this age it becomes to deteriorate and lose its youthful power and energy.

Scientists have been conducting different experiments on animals and humans to understand why do we age and how to stop this aging process some studies suggest that our cells are programmed to live only for a limited period of time and others believe that our cells have a limited division capability and after a certain period of time they can no longer replicate themselves and the individual starts to age.

But recently researchers have been able to increase the lifespan of lab rats by using a different combination of stem cell treatments. Stem cells are undistinguished cells in our body that have the potential to take form of different cells and perform different functions in the body, scientists have been able to replicate the stem cell to perform different functions of body to simulate better cell growth and help the mice to live longer.

Stem cells can be a very viable, cheap and safe method of treatment because stem cells are the part of the body and replicate the function of body they do not carry any contra-indications that may cause complications in the future but rather use the bodys natural healing and replicating power to cure the ailment that is present inside the host. Stem cells are widely used for organ regeneration, where a part or the entire organ has been lost due to some disease, doctors have been able to repair damage by injecting stem cells in the body. Several studies have been conducted where researchers have been able to cure blindness in old mice.

Cancer is one of the most evasive type of disease that affects millions of people around the world, it disrupts the balance of the body that may result in death but stem cell treatment has shown a lot of promise in this area and can help the doctors remove the faulty cells that have mutated using the stem cells therapy. Stem cells therapy is also widely used in dealing with sports related injuries, there have been hundreds of examples of athletes who have completed recovered without requiring any surgery by using stem cell treatment. Stem cells hold a lot of potential to help the humans discover cures for different ailments that are responsible for the death of thousands every year.

Distributed by NetJumps International

Media Contact Company Name: BioStem Technologies Contact Person: Jason Email: info@biostemtech.com Phone: (954) 380-8342 Country: United States Website: http://www.biostemtechnologies.com/

Link:
Beneficial use of stem cells and telomere science is to ...

Posted in Alaska Stem Cells | Comments Off on Beneficial use of stem cells and telomere science is to …

The Irvine Stem Cell Treatment Center Announces the …

Posted: July 2, 2015 at 12:51 am

The Sacramento office is set to open in California on July 11, 2015.

Sacramento, California (PRWEB) June 30, 2015

The Irvine Stem Cell Treatment Center announces the opening of a new office in Sacramento, California on July 11, 2015, with Dr. Thomas A. Gionis, Surgeon-in-Chief.

Our new office is located at the New Body MD Surgical Center, 1111 Exposition Blvd., Suite 400B, Sacramento, CA 95815. If you have any questions or would like further information please call us at (949) 679-3889.

The Irvine Stem Cell Treatment Center (Irvine; Westlake Village; and Sacramento, California), along with sister affiliates, the Miami Stem Cell Treatment Center (Miami; Boca Raton; Orlando; The Villages; Sarasota, Florida) and the Manhattan Regenerative Medicine Medical Group (Manhattan, New York), abide by approved investigational protocols using adult adipose derived stem cells (ADSCs) which can be deployed to improve patients quality of life for a number of chronic, degenerative and inflammatory conditions and diseases. ADSCs are taken from the patients own adipose (fat) tissue (found within a cellular mixture called stromal vascular fraction (SVF)). ADSCs are exceptionally abundant in adipose tissue. The adipose tissue is obtained from the patient during a 15 minute mini-liposuction performed under local anesthesia in the doctors office. SVF is a protein-rich solution containing mononuclear cell lines (predominantly adult autologous mesenchymal stem cells), macrophage cells, endothelial cells, red blood cells, and important Growth Factors that facilitate the stem cell process and promote their activity.

ADSCs are the bodys natural healing cells - they are recruited by chemical signals emitted by damaged tissues to repair and regenerate the bodys injured cells. The Irvine Stem Cell Treatment Center only uses Adult Autologous Stem Cells from a persons own fat No embryonic stem cells are used; and No bone marrow stem cells are used. Current areas of study include: Emphysema, COPD, Asthma, Heart Failure, Heart Attack, Parkinsons Disease, Stroke, Traumatic Brain Injury, Lou Gehrigs Disease, Multiple Sclerosis, Lupus, Rheumatoid Arthritis, Crohns Disease, Muscular Dystrophy, Inflammatory Myopathies, and Degenerative Orthopedic Joint Conditions (Knee, Shoulder, Hip, Spine). For more information, or if someone thinks they may be a candidate for one of the adult stem cell protocols offered by the Irvine Stem Cell Treatment Center, they may contact Dr. Gionis directly at (949) 679-3889, or see a complete list of the Centers study areas at: IrvineStemCellsUSA.com.

Also, you can listen and call into our new radio show, The Stem Cell Show, hosted by Dr. Gionis on TalkRadio 790 AM KABC, Sundays @ 4pm PST, or worldwide on KABC.com ("Listen Live" at 4pm PST) or the KABC app available on the App Store or Google Play.

About the Irvine Stem Cell Treatment Center: The Irvine Stem Cell Treatment Center, along with sister affiliates, the Miami Stem Cell Treatment Center and the Manhattan Regenerative Medicine Medical Group, is an affiliate of the California Stem Cell Treatment Center / Cell Surgical Network (CSN); we are located in Irvine, Westlake, and now Sacramento, California. We provide care for people suffering from diseases that may be alleviated by access to adult stem cell based regenerative treatment. We utilize a fat transfer surgical technology to isolate and implant the patients own stem cells from a small quantity of fat harvested by a mini-liposuction on the same day. The investigational protocols utilized by the Irvine Stem Cell Treatment Center have been reviewed and approved by an IRB (Institutional Review Board) which is registered with the U.S. Department of Health, Office of Human Research Protection (OHRP); and our studies are registered with Clinicaltrials.gov, a service of the U.S. National Institutes of Health (NIH). For more information, visit our websites: IrvineStemCellsUSA.com, MiamiStemCellsUSA.com, NYStemCellsUSA.com, or TheStemCellShow.com.

For the original version on PRWeb visit: http://www.prweb.com/releases/2015/06/prweb12760439.htm

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

Continued here:
The Irvine Stem Cell Treatment Center Announces the ...

Posted in West Virginia Stem Cells | Comments Off on The Irvine Stem Cell Treatment Center Announces the …

Wisconsin Roundup: VC Funding, StartUp Health, Stem Cells …

Posted: July 2, 2015 at 12:51 am

Heres a collection of recent headlines from Wisconsins innovation community:

Waukesha-based Elli Health has changed its name to Intellivisit and tacked nearly $400,000 on to a funding round that previously raised about $780,000, according to SEC filings. The companys software enables virtual doctor visits.

Madison-based Health eFilings raised $934,500 in a seed funding round that could reach $1.5 million, according to a new SEC filing. The company sells software that helps healthcare providers report care quality data as required by Medicare. The startup is led by Robert Hopton, whose previous company, Idle Free Systems, was acquired last year by Phillips & Temro Industries.

Madison-based Digsite raised $775,000 in a seed funding round, according to an SEC filing. The companys software provides private online forums for marketers, researchers, and digital agencies to interact with customers and share photos and videos from any device.

Aurora Health Care, the Milwaukee-based healthcare system serving eastern Wisconsin and northern Illinois, became a lead investor in StartUp Health, the New York-based company that invests in digital health startups and gives them access to mentors, industry connections, and business training services. The size of Auroras investment wasnt disclosed.

The Water Council received a $230,000 grant from JPMorgan Chase to continue providing specialized training for angel investors and programs to connect corporate innovation departments with water technology startups looking for investment capital. TheMilwaukee-based Water Council is in its second year of funding from a JPMorgan Chase small business funding program.

In other local water industry news, Milwaukee-based Rexnord (NYSE: RXN) announced its relocating the headquarters of its Zurn subsidiary from Pennsylvania to the Reed Street Yards near downtown Milwaukee, where a new water technology business park is being built next to The Water Councils Global Water Center. Zurn makes toilets, sinks, and a variety of other plumbing-related products.

Monona-based Shine Medical Technologies said it was awarded a $150,000 Phase 1 Small Business Innovation Research grant from the National Science Foundation. The money will go toward development of a process for extracting and purifying iodine-131, a type of medical isotope used in treating Graves disease and cancer, the company said. This is a potential product Shine could manufacture when it opens a facility in Janesville in a few years.

The primary material Shine has said it intends to produceat Janesville, though, is molybdenum-99, which then decays into technetium-99, the most common medical isotope injected into patients for medical scans to diagnose things like cancer and heart disease.

Madison-based WiCell, the nonprofit that provides stem cell banking and testing services, has been chosen to store and distribute the induced pluripotent stem cell lines from more than 1,500 donors as part of a five-year, $80 million program funded by the National Heart, Lung, and Blood Institute. The initiativedubbed Next Generation Genetic Association Studiesis investigating genetic variations in humans to learn more about diseases. Participating researchers hail from across the U.S., including the Medical College of Wisconsin, Boston University, Harvard University, Stanford University, UC-San Diego, and Scripps Research Institute.

View post:
Wisconsin Roundup: VC Funding, StartUp Health, Stem Cells ...

Posted in Wisconsin Stem Cells | Comments Off on Wisconsin Roundup: VC Funding, StartUp Health, Stem Cells …

Is testosterone replacement therapy safe? Take a look at …

Posted: July 2, 2015 at 12:50 am

Millions of American men use a prescription testosterone gel, patch, or injection to boost levels of the manly hormone. The ongoing marketing blitz promises that treating "low T" this way can make men feel more alert, energetic, mentally sharp, and sexually functional. However, legitimate safety concerns linger, as explained in the February 2014 issue of the Harvard Men's Health Watch.

"Because of the marketing, men have been flooded with information about the potential benefit of fixing low testosterone, but not with the potential costs," says Dr. Carl Pallais, an endocrinologist and assistant professor of medicine at Harvard Medical School. "Men should be much more mindful of the possible long-term complications."

Some studies have found that men taking testosterone have more cardiovascular problems, like heart attacks, strokes, and deaths from heart disease. Some physicians also have a lingering concern that testosterone therapy could stimulate the growth of prostate cancer cells. Yet the evidence is mixed, with some studies showing a lower cardiac risk with testosterone therapy and no apparent effect on prostate cancer.

In such uncertain times, men should take a cautious approach, Dr. Pallais says.

"I can't tell you for certain that taking testosterone raises the risk of heart problems and prostate cancer, or that it doesn't," Dr. Pallais says. "We need a large study with multiple thousands of men followed for many years to figure it out."

Until then, here are some tips for taking a cautious approach to testosterone therapy:

Read the full-length article: "Is testosterone therapy safe? Take a breath before you take the plunge"

February 1, 2014

Original post:
Is testosterone replacement therapy safe? Take a look at ...

Posted in Testosterone Replacement Therapy | Comments Off on Is testosterone replacement therapy safe? Take a look at …

regenerative medicine | Britannica.com

Posted: June 30, 2015 at 5:49 am

regenerative medicine,cartilage: bronchus repair using bioartificial tissue transplantationHospital Clinic of Barcelona/APthe application of treatments developed to replace tissues damaged by injury or disease. These treatments may involve the use of biochemical techniques to induce tissue regeneration directly at the site of damage or the use of transplantation techniques employing differentiated cells or stem cells, either alone or as part of a bioartificial tissue. Bioartificial tissues are made by seeding cells onto natural or biomimetic scaffolds (see tissue engineering). Natural scaffolds are the total extracellular matrixes (ECMs) of decellularized tissues or organs. In contrast, biomimetic scaffolds may be composed of natural materials, such as collagen or proteoglycans (proteins with long chains of carbohydrate), or built from artificial materials, such as metals, ceramics, or polyester polymers. Cells used for transplants and bioartificial tissues are almost always autogeneic (self) to avoid rejection by the patients immune system. The use of allogeneic (nonself) cells carries a high risk of immune rejection and therefore requires tissue matching between donor and recipient and involves the administration of immunosuppressive drugs.

A variety of autogeneic and allogeneic cell and bioartificial tissue transplantations have been performed. Examples of autogeneic transplants using differentiated cells include blood transfusion with frozen stores of the patients own blood and repair of the articular cartilage of the knee with the patients own articular chondrocytes (cartilage cells) that have been expanded in vitro (amplified in number using cell culture techniques in a laboratory). An example of a tissue that has been generated for autogeneic transplant is the human mandible (lower jaw). Functional bioartificial mandibles are made by seeding autogeneic bone marrow cells onto a titanium mesh scaffold loaded with bovine bone matrix, a type of extracellular matrix that has proved valuable in regenerative medicine for its ability to promote cell adhesion and proliferation in transplantable bone tissues. Functional bioartificial bladders also have been successfully implanted into patients. Bioartificial bladders are made by seeding a biodegradable polyester scaffold with autogeneic urinary epithelial cells and smooth muscle cells.

Another example of a tissue used successfully in an autogeneic transplant is a bioartificial bronchus, which was generated to replace damaged tissue in a patient affected by tuberculosis. The bioartificial bronchus was constructed from an ECM scaffold of a section of bronchial tissue taken from a donor cadaver. Differentiated epithelial cells isolated from the patient and chondrocytes derived from mesenchymal stem cells collected from the patients bone marrow were seeded onto the scaffold.

There are few clinical examples of allogeneic cell and bioartificial tissue transplants. The two most common allogeneic transplants are blood-group-matched blood transfusion and bone marrow transplant. Allogeneic bone marrow transplants are often performed following high-dose chemotherapy, which is used to destroy all the cells in the hematopoietic system in order to ensure that all cancer-causing cells are killed. (The hematopoietic system is contained within the bone marrow and is responsible for generating all the cells of the blood and immune system.) This type of bone marrow transplant is associated with a high risk of graft-versus-host disease, in which the donor marrow cells attack the recipients tissues. Another type of allogeneic transplant involves the islets of Langerhans, which contain the insulin-producing cells of the body. This type of tissue can be transplanted from cadavers to patients with diabetes mellitus, but recipients require immunosuppression therapy to survive.

Cell transplant experiments with paralyzed mice, pigs, and nonhuman primates demonstrated that Schwann cells (the myelin-producing cells that insulate nerve axons) injected into acutely injured spinal cord tissue could restore about 70 percent of the tissues functional capacity, thereby partially reversing paralysis.

embryonic stem cell: scientists conducting research on embryonic stem cellsMauricio LimaAFP/Getty ImagesStudies on experimental animals are aimed at understanding ways in which autogeneic or allogeneic adult stem cells can be used to regenerate damaged cardiovascular, neural, and musculoskeletal tissues in humans. Among adult stem cells that have shown promise in this area are satellite cells, which occur in skeletal muscle fibres in animals and humans. When injected into mice affected by dystrophy, a condition characterized by the progressive degeneration of muscle tissue, satellite cells stimulate the regeneration of normal muscle fibres. Ulcerative colitis in mice was treated successfully with intestinal organoids (organlike tissues) derived from adult stem cells of the large intestine. When introduced into the colon, the organoids attached to damaged tissue and generated a normal-appearing intestinal lining.

In many cases, however, adult stem cells such as satellite cells have not been easily harvested from their native tissues, and they have been difficult to culture in the laboratory. In contrast, embryonic stem cells (ESCs) can be harvested once and cultured indefinitely. Moreover, ESCs are pluripotent, meaning that they can be directed to differentiate into any cell type, which makes them an ideal cell source for regenerative medicine.

Studies of animal ESC derivatives have demonstrated that these cells are capable of regenerating tissues of the central nervous system, heart, skeletal muscle, and pancreas. Derivatives of human ESCs used in animal models have produced similar results. For example, cardiac stem cells from heart-failure patients were engineered to express a protein (Pim-1) that promotes cell survival and proliferation. When these cells were injected into mice that had experienced myocardial infarction (heart attack), the cells were found to enhance the repair of injured heart muscle tissue. Likewise, heart muscle cells (cardiomyocytes) derived from human ESCs improved the function of injured heart muscle tissue in guinea pigs.

Derivatives of human ESCs are likely to produce similar results in humans, although these cells have not been used clinically and could be subject to immune rejection by recipients. The question of immune rejection was bypassed by the discovery in 2007 that adult somatic cells (e.g., skin and liver cells) can be converted to ESCs. This is accomplished by transfecting (infecting) the adult cells with viral vectors carrying genes that encode transcription factor proteins capable of reprogramming the adult cells into pluripotent stem cells. Examples of these factors include Oct-4 (octamer 4), Sox-2 (sex-determining region Y box 2), Klf-4 (Kruppel-like factor 4), and Nanog. Reprogrammed adult cells, known as induced pluripotent stem (iPS) cells, are potential autogeneic sources for cell transplantation and bioartificial tissue construction. Such cells have since been created from the skin cells of patients suffering from amyotrophic lateral sclerosis (ALS) and Alzheimer disease and have been used as human models for the exploration of disease mechanisms and the screening of potential new drugs. In one such model, neurons derived from human iPS cells were shown to promote recovery of stroke-damaged brain tissue in mice and rats,
and, in another, cardiomyocytes derived from human iPS cells successfully integrated into damaged heart tissue following their injection into rat hearts. These successes indicated that iPS cells could serve as a cell source for tissue regeneration or bioartificial tissue construction.

Scaffolds and soluble factors, such as proteins and small molecules, have been used to induce tissue repair by undamaged cells at the site of injury. These agents protect resident fibroblasts and adult stem cells and stimulate the migration of these cells into damaged areas, where they proliferate to form new tissue. The ECMs of pig small intestine submucosa, pig and human dermis, and different types of biomimetic scaffolds are used clinically for the repair of hernias, fistulas (abnormal ducts or passageways between organs), and burns.

See the original post:
regenerative medicine | Britannica.com

Posted in Regenerative Medicine | Comments Off on regenerative medicine | Britannica.com

Role of Bacteria in Environment – Biotechnology Forums

Posted: June 30, 2015 at 5:48 am

Bacteria are the unicellular organisms and cannot be seen with naked eye. There is no particular method of cell division, they simply divide by binary fission in which cell divides into two daughter cells. They do not have proper nucleus within the cell but the genetic material is attached to the cell membrane in an irregular form. They are found everywhere like top of the mountains, rivers, on land and in ice. Bacteria have the property of living in extreme weathers like extreme cold and extreme heat. They are able to live long because they become inactive for a long period of time.

Bacteria play an important role in the environment: Decomposition of Dead/Complex Organic Matter:

Ever imagined the fate of nature with dead matter of animals/plants lying around? Bacteria play a very crucial role of silently getting the nature rid of the dead matter through the decomposition of dead organic matter by the micobes. Bacteria use them as a source of nutrients, and in turn help in recycling the organic compounds trapped in the dead matter. Through this process, other organisms also get benefited, who can use the simpler forms of organic compounds/nutrients released from the dead matter by various bacteria.

Bioremediation by bacteria Bioremediation refers to the process of depletion/degradation of toxic compounds present in the natural environment by living organisms. Bacteria are one of the key players in Bioremediation. For example, oil spills due to oil digging operations or accidents on oil transport channels in the ocean or on the soil, is highly determinant to the healthy environment. Bacteria like Pseudomonas have been well known for the degradation of oil spills on oceans/soils.

Similarly, Contamination of heavy metals in the environment is a major global concern because of their toxicity and

threat to human life and environment. Bacteria like Alcaligenes faecalis (Arsenic),Pseudomonas fluorescens and Enterobacter clocae (Chromium) are well known for heavy metal uptake/compound metabolism. Waste Water Treatment Owing to their characteristics of degrading harmful chemicals and pollutants, bacteria naturally (as well as deliberately used by industries), help in treatment of waste water.

Image source: biologia.laguia2000.com

See the original post here:
Role of Bacteria in Environment - Biotechnology Forums

Posted in Biotechnology | Comments Off on Role of Bacteria in Environment – Biotechnology Forums

De-Differentiation of Somatic Cells to a Pluripotent State …

Posted: June 29, 2015 at 1:45 am

Posted in Delaware Stem Cells | Comments Off on De-Differentiation of Somatic Cells to a Pluripotent State …

Associate Professor – IPSC Stem Cells (Days / Full-Time …

Posted: June 29, 2015 at 1:45 am

Jobing Description

FACULTY POSITION IN NEUROSCIENCE RESEARCH

The BARROW NEUROLOGICAL INSTITUTE seeks an exceptionally promising or accomplished investigator to complement other translational neuroscience research in a unique and dynamic environment including the BNI and partnering institutions. Qualified applicants holding M.D., Ph.D. or equivalent degrees with five (5) years post graduate or faculty-level experience will be considered for appointment at assistant, associate or full professor levels. The successful candidate will also have a joint faculty appointment in the Department of Basic Medical Sciences at the University of Arizona College of Medicine Phoenix. Successful candidates will be expected to orchestrate a program of extramurally-funded, independent research and to assume educational and administrative responsibilities. Institutional strategic interests for this initiative are in application of inducible pluripotent stems cells (IPSC) toward research and treatment of neurodegenerative conditions, particularly amyotrophic lateral sclerosis. Qualified applicants in other areas of translational neuroscience that utilize IPSC will also be considered. The successful candidate is expected to synergize/collaborate with existing faculty at both institutes, with access to resources (core facilities, clinical samples, etc.) across both institutes, and opportunities to collaborate with investigators at affiliate institutes including Phoenix Children's Hospital, the Translational Genomics Research Institute, and the Arizona Alzheimer's Consortium. The successful candidate will receive a highly competitive start-up package and salary support. Please send either an initial letter of inquiry in confidence or a full application including vita, names and addresses of three references, and brief statements of research experience, interests and career objectives either as hard copies to IPSC Search, c/o Research Administration, Barrow Neurological Institute, 350 West Thomas Road, Phoenix, AZ 85013 or via e-mail message and attachment to BNI_Research@dignityhealth.org and apply online at: http://www.dignityhealthcareers.org AA/EOE.

Located conveniently in the heart of Phoenix, Arizona,St. Joseph's Hospital and Medical Center is a 450 bed, not-for-profit hospital that provides a wide range of health, social and support services. We are extremely proud to be a nationally recognized center for quality tertiary care, medical education and research. St. Joseph's includes the internationally renowned Barrow Neurological Institute, St. Joseph's Heart & Lung Institute, the University of Arizona Cancer Center at St. Joseph's, and St. Joseph's Level I Trauma Center (which is verified by the American College of Surgeons). The hospital is also a respected center for high-risk obstetrics, neuro rehabilitation, orthopedics, and other medical services.

U.S News & World Report routinely ranks St. Joseph's among the top hospitals in the United States for neurology and neurosurgery. In addition, St. Joseph's boasts the Creighton University School of Medicine at St. Joseph's, a strategic alliance with Phoenix Children's Hospital, and a partnership with The University of Arizona Cancer Center.

Founded in 1895 by the Sisters of Mercy, St. Joseph's was the first hospital in the Phoenix area. More than 117 years later, St. Joseph's remains dedicated to its mission of caring for the poor and underserved.

St. Joseph's is consistently named an outstanding place to work and one of Arizona's healthiest employers. Come grow your career with one of Arizona's Most Admired Companies

Look for us on Facebook and follow us on Twitter

For the health of our community ... we are proud to announce that we are a tobacco-free campus.

Dignity Health is an Equal Opportunity / Affirmative Action employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, national origin, disability, or protected Veteran status. For more information about your EEO rights as an applicant, please click here.

Follow this link:
Associate Professor - IPSC Stem Cells (Days / Full-Time ...

Posted in Arizona Stem Cells | Comments Off on Associate Professor – IPSC Stem Cells (Days / Full-Time …

Stem cell expert: Bart Starr treatment shows need for …

Posted: June 29, 2015 at 1:44 am

The news that legendary Green Bay Packer quarterback Bart Starr has undergone stem cell therapy to recover from a stroke has raised the profile for a promising but unproven regenerative treatment intended to replace dead neurons with live ones.

The University of Wisconsin-Madison's Su-Chun Zhang was the first scientist to isolate neural stem cells from embryonic stem cells and then from other types of all-purpose stem cells. He says medical researchers and the federal government have a responsibility to forge ahead with clinical trials to prove whether and how these flexible cells can replace damaged or dead neural cells caused by spinal cord injury, stroke and Lou Gehrig's disease (ALS).

"We have no effective treatment for stroke," says Zhang, a medical doctor and Ph.D. researcher at the UW's Waisman Center. "After a couple of hours, the cells are dead if they don't have a blood supply. And the brain has a very limited capacity to regenerate, particularly in older patients."

Embryonic stem cells the cells that give rise to all body tissues were first cultured by James Thomson at UW-Madison in 1998. Just three years later in 2001 Zhang discovered how to grow neural cells from embryonic stem cells.

Since then, he has been instrumental in differentiating these neural cells into neurons, which carry nerve signals, and glial cells, which keep neurons healthy. UW-Madison currently has more than 90 faculty working on the basic science and regenerative potential of stem cells. UW scientists publish more than 500 research articles each year on stem cells.

Zhang expressed hope that Starr will recover, but says there are plenty of question marks, such as what type of cells were used, and how they were inserted into the body.

In a statement Wednesday, Starr's family announced he was participating in a stem-cell trial but gave no details of how or where he was being treated. Published reports have said that the family received information about stem-cell treatment in Tijuana, Mexico, undergone by hockey Hall-of-Famer Gordie Howe.

Given the lack of available therapies for stroke in the U.S., treatments and trials outside the country can understandably appeal to patients and families searching for help.

But Zhang says there are questions about whether foreign trials meaningfully advance the science of the field. Curious about the widespread clinical trials for stem cell therapy said to be underway, he says he "went through lists of thousands of clinical trials, mostly in foreign countries, looking for the outcomes, and I hardly saw any posted results." Patients usually disappear after returning home, he says, "and many of these so-called trials are not really trials, where you follow the patient and set up standards to measure the outcome. What do they teach you?"

Read the rest here:
Stem cell expert: Bart Starr treatment shows need for ...

Posted in Wisconsin Stem Cells | Comments Off on Stem cell expert: Bart Starr treatment shows need for …

Stem Cell Assays Reproducible Research on Stem Cells

Posted: June 27, 2015 at 8:42 pm

As you may know, Im trying to capture all stem cell products available on a market worldwide. I realized that there are two groups of such products the first is the products, approved by governmental regulatory agencies (usually considered drugs) and the second is so-called self-launched not approved cell/ tissue products. Today, Id like to discuss some issues, related to second group of commercial stem cell products.

Examples of self-launched cell/tissue products:

Common features of these products:

Regulatory compliance As I noted above, self-proclaimed regulatory compliance of these product turns out to be a false. In the last 5 years FDA inspected these companies and issued a number of quite similar letters. Some of these letters:

These letters indicate to non-compliant marketing of the products, which misclassified by companies as 361 HCT/P, instead of drugs (351). Interestingly, most of these products stayed on a market (AlloStem, Ovation/ BIO4), despite FDAs warnings.

Business model Despite FDA early letters (from Parcell and AlloSource in 2011), the companies continued to do the same thing over and over again in 2013 (Osiris) and in 2014 (RTI Surgical). Very recent deal between Stryker and Osiris on transformation of Ovation into BIO4 is an example of continuing trend. Why didnt they learn? Did they miss those FDA letters? Did they consult with FDA on classification of their products? Do they actually care at all about FDAs current thinking? NO, NO and NO! It indicates that self-launch and self-claims are working well for a profit. It seem to me, their regulatory compliance people did not do homework or were asked to follow the scheme: - dont consult with FDA! - self-launch it with fancy label stem cell! - pitch it to surgeons they like to be innovative and push an envelope! - enjoy a ride $$$ until FDA will crack down on you. Why this business model is still thriving? Well, first of all, FDA may never come to you (they have limited resources) if you dont kill any patient. Second, if FDA will sniff you, it may take 1-2 years before audit, months for report, 1 year for responses and so on. Third, companies may get away with it by pleasing or negotiating with FDA (Osiris did it for Grafix) changing marketing language (Biomet removed all osteogenic cells/ MSC-related language from description of Cellentra as advertised earlier in 2012) , narrowing down therapeutic indications, promise to do some post-marketing studies. Another possible model is divesting a product (Osiris sold Osteocel to NuVasive), partnership with big players (Osiris Stryker deal).

Id like to give one more example of changing a marketing language about products in order to become pseudo-compliant. Nutech widely advertised their product Nucel as containing amniotic (stem) cells along with amniotic membrane (examples here and here). However, watching FDA cracking down on some 361 products and reading FDA updates (see the first update of 2012 from FDA Tissue Reference Group), they decided to tune up language and removed a mention of cells from their web site. Compliance is done? Very simple fix remove word cells from everywhere!

Therapeutic efficacy There are very little good published clinical data available about efficacy of these products. If we look at orthobiologics, things are not so positive as one may think. For example, the recent report on efficacy of Osteocel (NuVasive) in matched cohort spinal fusion, was negative:

This is the first non-industry sponsored study to analyze a matched cohort assessing the one-year arthrodesis rates associated with a non-structural MSC allograft in one and two-level ACDF procedures. There were no statistically significant differences in fusion rates between the two cohorts.

The recent overview (highly recommended!) of commercially available cellular bone matrices in spinal surgery, came up with the following conclusions:

See the rest here:
Stem Cell Assays Reproducible Research on Stem Cells

Posted in Stem Cell Research | Comments Off on Stem Cell Assays Reproducible Research on Stem Cells

Page 1,779«..1020..1,7781,7791,7801,781..1,7901,800..»